
Contingent Value Rights in 2026 Biopharma Take-Privates — What the Triggers Actually Pay, After the $180 Million Syntimmune Ruling
CVRs look like earnouts but Delaware treats them differently. The 2024 Alexion/Syntimmune ruling and the resulting $180 million damages award reset the efforts-standard analysis for biopharma deals.
